Literature DB >> 7571398

Human papillomavirus type 11 transcripts are present at low abundance in latently infected respiratory tissues.

A Maran1, C A Amella, T P Di Lorenzo, K J Auborn, L B Taichman, B M Steinberg.   

Abstract

Respiratory tract tissues containing latent human papillomavirus (HPV) 11 were analyzed by reverse transcription-polymerase chain reaction for the presence of viral-specific RNA from the early region of the genome and compared to a similar analysis of laryngeal papillomas. Latently infected tissue contained low-abundance transcripts that could code for E1 and E2 proteins, but lacked evidence of spliced transcripts for the E6 and E7 proteins. Both latently infected tissue and papilloma tissue contained low-abundance antisense transcripts. Cultured cells infected with HPV 11 virions or transfected with HPV DNA, and cells derived from latently infected tissue, expressed transcripts similar to those seen in papillomas, but at a lower abundance. We postulate that latency is determined by the absence of or limiting levels of critical viral proteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571398     DOI: 10.1006/viro.1995.1486

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA.

Authors:  E R Jensen; R Selvakumar; H Shen; R Ahmed; F O Wettstein; J F Miller
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Differential effects of the splice acceptor at nucleotide 3295 of human papillomavirus type 31 on stable and transient viral replication.

Authors:  D J Klumpp; F Stubenrauch; L A Laimins
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 3.  How virus persistence can initiate the tumorigenesis process.

Authors:  Simone Avanzi; Gualtiero Alvisi; Alessandro Ripalti
Journal:  World J Virol       Date:  2013-05-12

4.  Differences in C/EBPs in normal tissue and papillomas of the larynx.

Authors:  L Jin; G Y Yang; K Auborn
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

5.  CCAAT displacement protein, a regulator of differentiation-specific gene expression, binds a negative regulatory element within the 5' end of the human papillomavirus type 6 long control region.

Authors:  S Pattison; D G Skalnik; A Roman
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease.

Authors:  A Vambutas; V R Bonagura; B M Steinberg
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

Review 7.  A possible role for human papillomaviruses in head and neck cancer.

Authors:  B M Steinberg; T P DiLorenzo
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

8.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

Authors:  James A DeVoti; Bettie M Steinberg; David W Rosenthal; Lynda Hatam; Andrea Vambutas; Allan L Abramson; Mark J Shikowitz; Vincent R Bonagura
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

9.  Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.

Authors:  Vincent R Bonagura; Zeying Du; Elham Ashouri; Lihui Luo; Lynda J Hatam; James A DeVoti; David W Rosenthal; Bettie M Steinberg; Allan L Abramson; David W Gjertson; Elaine F Reed; Raja Rajalingam
Journal:  Hum Immunol       Date:  2009-10-25       Impact factor: 2.850

10.  Propagation of infectious human papillomavirus type 16 by using an adenovirus and Cre/LoxP mechanism.

Authors:  John H Lee; Su Min P Yi; Mary E Anderson; Kristi L Berger; Michael J Welsh; Aloysius J Klingelhutz; Michelle A Ozbun
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.